Miniaturized Extraction Techniques in Drug Biotransformation Studies by using Endophytic Fungi Cunninghamella elegans

Method transfer between bioanalytical laboratories.

A pharmaceutical industry is highly regulated by a quality policy in its management. The principles of Quality by Design (QbD) must be applied to ensure the development of pragmatic and systematic methods while managing the risks associated with analytical methods. Quality by Design (QbD) is a scientific way to develop easy and robust analytical techniques for critical analysis. Quality by Design (QbD) is a systematic approach to product or method development that starts with predetermined goals and uses a science and risk management approach to achieve product and method understanding. The concept of risk management is deeply integrated into the quality assurance system to ensure pharmaceutical quality and patient safety. In the context of quality control, detecting impurities in raw materials and finished products is a major concern. Analytical Quality by Design (AQbD) aims to achieve quality in measurement. The main objectives are to explain the various steps involved in developing a method using a Quality by Design (QbD) approach for the development of analytical methods and to explain the implementation of Quality by Design (QbD) in the validation of analytical procedures. The advantages of applying Quality by Design (QbD) principles to analytical techniques include finding and minimizing sources of variability that could lead to poor method robustness and ensuring that the method meets the desired performance requirements over the product and method life cycle. The Analytical Quality by Design (AQbD) strategy is increasingly being adopted as it allows an early understanding of the method and guarantees the determination of a wider set of experimental conditions.

Quality by Design is the most recent quality-related trend in pharmaceutical manufacturing (QbD). This paper discusses Pharmaceutical Quality by Design (QbD) as a way to guarantee high-quality pharmaceuticals. Details about Quality by Design are given in addition to a list of its components. The quality parameters and attributes of each unit operation are unique. Pharmaceutical products can benefit from Quality by Design and the steps that can be taken to implement it. High-quality pharmaceuticals and their manufacturing processes form the core of pharmaceutical R&D. It is impossible to verify the quality of a product because this document includes a breakdown of the product's quality profile and the most important aspects of Quality by Design. Comparing the quality of various products can be done in two ways: through Quality by Design and end-product testing (QbD). Quality by Design is based on the ICH Guidelines. ICH guidelines govern the development of pharmaceuticals and the implementation of quality assurance systems. Pharmaceutical development and production can benefit from Quality by Design (QbD).
 Keywords: Concept & background of QbD, Traditional vs QbD Approach, Key elements, PAT, Challenges, Current & Future perspective.

Abstract: Recent changes and limited resources for drug development and manufacturing have rendered the conventional pharmaceutical quality assurance approach insufficient and have given rise to new research in these areas. To address these research efforts, the FDA improved and modernized the rules governing pharmaceutical manufacturing and product quality in 2002, thereby realizing a paradigm change in the current Good Manufacturing Practices (cGMP). The Quality by Design (QbD) approach has entered the pharmaceutical industry within the last 10 years after the approval of the ICH Q8 in 2005. QbD is based on an understanding of the target product’s quality profile (QTPP) and an assessment of its risks during the design and development of pharmaceutical dosage forms. By determining the critical quality attributes of the drug, including its active ingredient, its excipients, and the processes and design spaces used during the R&D phase, multi-way tracking during the life cycle of the drug can be achieved. This tracking can provide numerous advantages, including flexibility in licensing by decreasing the variation and type modifications in applications of the pharmaceutical product, which result from minimizing the possible issues arising after the release of the product. When all these data are observed, it is clear that the new QbD approach benefits the authorities, the drug manufacturers and the patient. Although QbD has certain challenges during its early stages, it is thought that QbD will benefit pharmaceutical manufacturers. Keywords: Quality by design (QbD), target product quality profile, critical quality attributes, design space, risk assessment.

‘Quality by Design’ approach for the analysis of impurities in pharmaceutical drug products and drug substances

Quality by design (QbD) is an essential part of the modern advance to pharmaceutical quality. Quality has been given an importance by all regulatory body for pharmaceutical products. Quality means customer satisfaction in terms of service, products, and process. QbD is best key to build a quality in all pharmaceutical products. This paper gives idea about the Pharmaceutical Quality by Design (QbD) and describes use of Quality by Design to ensure quality of Pharmaceutical Analysis. Under this concepts of be throughout design and growth of product, it is important to identify desire product performance report Target product profile (TPP), Quality Target product profile (QTPP) and identify critical quality attributes (CQA). To recognize the impact of raw material critical material attributes (CAM), critical process parameters (CPP) on the CQAs and identification and control sources of changeability. USFDA launched a pilot programme in 2005 to permit participating firms a prospect to submit chemistry, manufacturing, and controls (CMC) of NDA information representing application of QbD. QbD has its perspectives to contribute the drug design, development, and manufacture of high-quality drug products. In the present review basic consideration of the QbD approach, its historical background, and regulatory needs are discussed. In detail explanation of elements of QbD i.e. method intent, design of experiment, and risk assessment is given. The foundation of Quality by Design is ICH Guidelines. It is based on the ICH Guidelines Q8 for pharmaceutical development, Q9 for quality risk management, Q10 for pharmaceutical quality systems. It also gives application of Quality by Design in pharmaceutical development and manufacturing of pharmaceuticals. Keywords: Quality by design, Critical Quality Attributes, Pharmaceutical Analysis, Design Of Experiment, Risk Assessment, Regulatory.

Introduction: The traditional development processes use a quality by testing (QbT) approach that needs continuous testing to determine quality. Such processes are fixed, averse to change, and focus only on process reproducibility. This approach does not allow variation in material and process controls. In order to overcome the shortcomings of the traditional process, regulatory bodies have issued guidelines for the industries to improve the understanding of the process and the quality of the product. It aims to shift from traditional process QbT to a scientific approach quality by design (QbD) to assure product quality in the pharmaceutical industry.
 Methodology: Articles related to QbD published in many search engines such as Scopus, Google Scholar, and PubMed were reviewed.
 Review Findings: In order to ensure the quality of pharmaceutical products, regulatory bodies have emphasized on the implementation of QbD. For this, various guidelines have been published from time to time. The Indian pharmaceutical industry has started to apply the principles of QbD. Implementation of QbD develops a detailed understanding of the manufacturing process. The design space is achieved by QbD within which the expected quality is achieved even with changes in process parameters.
 Conclusion: In short, the QbD approach is a great tool for assuring pharmaceutical product quality and better understanding of the manufacturing process. Therefore, it is imperative to have a successful implementation of the QbD approach.

QbD, or Quality by Design, is a cutting-edge methodology adopted extensively in the pharmaceutical industry. It is defined objects, such as the product's safety and effectiveness. QbD's primary focus in the pharmaceutical industry is ensuring the product's security and usefulness. Quality by Design (QbD) seeks to instill high standards of excellence in the blueprinting process. The International Council for Harmonization (ICH) has developed guidelines and elements that must be adhered to guarantee the consistent, high-quality development of pharmaceuticals. This chapter provides updated guidelines and elements, including quality risk management, pharmaceutical quality systems, QbD in analytical methods and pharmaceutical manufacturing, process control, vaccine development, pharmacogenomic, green synthesis, etc. QbD was briefly defined, and several design tools, regulatory-industry perspectives, and QbD grounded on science were discussed. It was portrayed that significant effort was put into developing drug ingredients, excipients, and manufacturing processes. Quality by design (QbD) is included in the manufacturing process's development, and the result is steadily improving product quality. Quality target product profiles, critical quality attributes, analytical process techniques, critical process parameters control strategy and design space are elements of many pharmaceutical advancements. Some of the topics covered included the application of QbD to herbal products, food processing, and biotherapeutics through analytical process techniques. We are still exploring and compiling all the data and metrics required to link and show the benefits of QbD to all stakeholders. Nevertheless, the pharmaceutical sector is quickly using the QbD process to create products that are reliable, efficient, and of high quality. Soon, a more profound comprehension of the dosage form parameters supported by the notion of QbD will benefit Risk management and process and product design, optimizing complex drug delivery systems.

Quality by Design (QbD) has become a new concept for development of quality pharmaceutical products, It is an essential part of the modern approach to pharmaceutical quality, QbD is a best solution to build a quality in all pharmaceutical products but it is also a major challenge to the Pharmaceutical industry whose processes are fixed in time, despite inherent process and material variability, Under this concept of QbD throughout designing and development of a product, it is essential to define desire product performance profile [Target product Profile (TPP), Target Product Quality Profile (TPQP)] and identify critical quality attributed (CQA). On the basis of this we can design the product formulation and process to meet the product attributes. This leads to recognise the impact of raw materials [critical material attributes (CMA)], critical process parameters (CPP) on the CQAs and identification and control sources of variability. QbD is an emerging idea which offers pharmaceutical manufacturer with increased self-regulated flexibility while maintaining tight quality standards and real time release of the drug product, This paper discusses the pharmaceutical QbD and describes how it can be used to develop the pharmaceutical products well within the specified period of time.

The elements of quality by design are examined and a consistent nomenclature for quality by design, critical quality attribute, critical process parameter, critical material attribute, and control strategy is proposed. A process is well understood when all critical sources of variability are identified and explained, variability is managed by the process, and product quality attributes can be accurately and reliably predicted over the design space. Quality by Design (QbD) is a systematic approach to development of products and processes that begins with predefined objectives and emphasizes product and process understanding and process control based on sound science, statistical methods and quality risk management. In an attempt to curb rising development costs and regulatory barriers to innovation and creativity, the FDA and ICH have recently started promoting QbD in the pharmaceutical industry [1, 3, 7,]. QbD is partially based on the application of multivariate statistical methods [2, 4, 6] and a statistical Design of Experiments strategy [4, 5, 6] to the development of both analytical methods and pharmaceutical formulations. The talk will review the basics of QbD with case studies from the pharmaceutical industry

Quality by design in pharmaceutical manufacturing: A systematic review of current status, challenges and future perspectives

Over the last years, the pharmaceutical industry has faced real challenges regarding quality assurance. In this context, the establishment of more holistic approaches to the pharmaceutical development has been encouraged. The emergence of the Quality by Design (QbD) paradigm as systematic, scientific and risk-based methodology introduced a new concept of pharmaceutical quality. In essence, QbD can be interpreted as a strategy to maximize time and cost savings. An in-depth understanding of the formulation and manufacturing process is demanded to optimize the safety, efficacy and quality of a drug product at all stages of development. This innovative approach streamlines the pharmaceutical Research and Development (R&D) process, provides greater manufacturing flexibility and reduces regulatory burden. To assist in QbD implementation, International Conference on Harmonisation (ICH), U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) organized and launched QbD principles in their guidance for industry, identifying key concepts and tools to design and develop a high-quality drug product. Despite the undeniable advantages of the QbD approach, and the widespread information on QbD regulatory expectations, its full implementation in the pharmaceutical field is still limited.The present review aims to establish a crosswise overview on the current application status of QbD within the framework of the ICH guidelines (ICH Q8(R2) - Q14 and ICH Q2(R2)). Moreover, it outlines the way information gathered from the QbD methodology is being harmonized in Marketing Authorization Applications (MAAs) for European market approval. This work also highlights the challenges that hinder the deployment of the QbD strategy as a standard practice.

A rapid and highly sensitive ultra-performance liquid chromatographic (UPLC) method was developed for analysis of docetaxel trihydrate in human plasma employing the analytical Quality by Design (QbD) approach. The quality target method profile (QTMP) was defined and critical analytical attributes (CAAs) earmarked. Unlike the chromatographic methods reported in literature including the official compendiums focusing on selecting buffer species as mobile phase mixture, acetonitrile and water (60:40 %v/v) was explored as the simpler solvent system along with rational understanding of the method performance through systematic approaches. Risk assessment and factor screening studies helped in identifying mobile phase ratio and injection volume as the critical method parameters (CMPs), followed by method optimization employing face-centred cubic design (FCCD). Search for optimum chromatographic conditions was carried out through numerical desirability function and graphical optimization. Method validation studies were also performed indicating high linearity, accuracy, precision, sensitivity of the method, along with adequate stability of the docetaxel trihydrate in human plasma. The studies successfully demonstrate the utility of analytical QbD approach for the development of a novel and validated bioanalytical method for estimation of docetaxel trihydrate in human plasma with enhanced method performance. Keywords: Design of Experiments, detection limit, linearity range, method validation, Quality by Design, risk assessment.

The purpose of this study was to investigate and analyze the application status and system introduction perceptions of quality-by-design (QbD) in domestic pharmaceutical companies and confirm the necessity of introducing an effective QbD system. Currently, QbD-applied drug development is an international trend, and the introduction of QbD domestically is urgent because domestic pharmaceutical companies need QbD data even when exporting overseas. Therefore, 51 domestic pharmaceutical companies were surveyed to analyze their perceptions and opinions on the current status of QbD application and the introduction of the system. The results showed that most pharmaceutical companies, except 4.7% of total respondents, recognized the need for QbD for the following reasons: to improve the quality of medicines, responding to requests from overseas regulatory authorities when exporting products, problem-solving drug development and production, and proactively responding to the introduction of the QbD system by the Ministry of Food and Drug Safety. Although they are aware of its need, respondents are not implementing QbD due to cost and time issues and state that it is challenging to apply the QbD example in practice due to the method and amount of experimentation. Thus, the results of this study revealed that domestic pharmaceutical companies need QbD experimental and process guidelines and practical QbD examples. These results can be used as the foundation for the introduction and stable settlement of a domestic QbD system in the future.

A rapid, sensitive, and reliable quality by design (QbD) based bioanalytical HPLC method was developed and validated for quantification of dapagliflozin (DFG) in rat plasma. The method was optimized using three levels and three-factor Box–Behnken statistical design (BBD). The mobile phase composition (acetonitrile % as A), flow rate (mL/min as B) and UV-wavelength (nm as C) selected as independent variable whereas area (AU as Y1), retention time (min. as Y2) and tailing factor (% as Y3) selected as dependent variables. The developed method validated for linearity, sensitivity (LOD & LOQ), precision, accuracy, extraction recovery, matrix effect, and stability. Further the developed bioanalytical used to assess the pharmacokinetic study on a rat model. The developed method showed excellent linearity between 10 and 1200 ng/mL with r2 = 0.997, LOD (2.15 ng/mL) and LOQ (6.52 ng/mL). The validation results of the tested parameters were found within the acceptable limit. Further, DFG loaded S-SNEDDS showed the droplet size (75.34 ± 5.34 nm), PDI (0.426) and zeta-potential (−25.6 mV). The pharmacokinetic study results revealed the Cmax of S-SNEDDS was 1.42 fold higher than DFG dispersion. The significantly high AUC value observed with S-SNEDDS indicated increased bioavailability of DFG as compared to DFG dispersion. From the study, it was concluded that QbD approach based bioanalytical method is suitable for the in-vitro and in-vivo estimation of DFG from bulk as well as developed formulations.